1/ In this #OriginalResearch paper in @ahajournals.bsky.social, Bellamo et al evaluate Lp(a) as a prognostic marker for incident and secondary vascular disease in participants from the UK Biobank

Here's a🧵summarizing key aspects of paper

🔗http://bit.ly/3HkLhP6

Let’s unpack the findings ⤵️

Thank you #AHAJournals for the opportunity to serve as Social Media Editor!

4/ 🌟TAVR has demonstrated safety and efficacy as an alternative to surgical intervention in lower-risk patients aged 60 to 75 with tricuspid AS, showing comparable outcomes to surgery over a three-year follow-up period, along with superior hemodynamic performance

3/ At 3 years:
🫀Similar rates of structural valve deterioration (≥moderate) 4.5% TAVR vs 5.2% surgery;
🫀Lower rates of bioprosthetic valve dysfunction with TAVR (11.9% vs. 21%);
🫀Similar rates of bioprosthetic valve failure (1.6% vs 2.9%).

2/
🫀Primary composite (death, stroke or valve/procedure/HF related hospitalization): 16.1% TAVR vs 12.6% surgery -> no significant difference.
🫀In bicuspid valve patients, outcomes favored surgery, though not statistically significant. #SoMeEditor #CardioTwitter #TAVR

Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis | Circulation Background: Transcatheter aortic valve replacement (TAVR) is increasingly performed in younger, low surgical risk patients. This NOTION-2 study reports mid-term outcomes in low-risk patients aged 60-7...

1/ #AHAJournals #ESC2025 #SimPub alert

🫀The NOTION-2 trial presents 3-year outcomes for 370 low-risk patients, aged 60-75 with a mean STS score of 1.2%, who have severe AS and were randomized to either TAVR or surgery.
🫀27% of these patients had a native bicuspid valve.

🔗 bit.ly/4g9zwYI

Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants | Circulation Background: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder primarily linked to rare variants in sarcomere genes, though recently certain non-sarcomeric genes have emerged as...

🚨 New @CircAHA #ESC2025 SimPub alert!
🚨 HCM isn’t just driven by rare Mendelian mutations. This study highlights the role of intermediate-effect variants (IEVs)—variants with moderate effect & low penetrance—in shaping disease expression. #HCM #SoMeEditor

tinyurl.com/HCM-IEVs

⏰ The countdown is on for #SCAI2025! I’ll be sharing key insights from this
premier #InterventionalCardiology event. What sessions are you most looking
forward to? Let me know below! 👇 @scainews.bsky.social #SoMe Ambassador for #SCAI2025! #SCAI #CardioSky #SCAIWIN #WIC #Medicine #ACCWIC #ACCFIT

🚀 Excited to be an official #SoMe Ambassador for #SCAI2025! Join me
May 1–3 in Washington, D.C. for cutting-edge education, networking, and
innovation in #InterventionalCardiology. Follow along for live updates! 🔗
scai.org/scai2025 #SCAI @scainews.bsky.social #CardioSky